Displaying items by tag: stocks
Goldman Sachs went on the record with a bold call last week. They told investors that despite all the fears in the market, a big correction WAS NOT coming. Alessio Rizzi and his team at Goldman say that many indicators are showing a bullish outlook, and that big losses don’t seem likely. According to Rizzi, “more moderate risky asset returns are likely from here, rather than an imminent risk of a sizable correction”. One indicator Goldman cited as very bullish was the ratio between puts and calls. Right now the market is deeply favoring calls, with the ratio nearing the limits of its normal distribution.
FINSUM: So bulls look at this and say “aha, I’m right, the market will rise”; and bears say “exactly as expected, this is a contrarian indicator”! In our opinion, on the whole, there is plenty to be optimistic about.
Tech shares have been doing very well recently. This has given rise to renewed fears of overvaluation and a market correction. In the ten days leading up to December 8th,the Nasdaq 100 jumped 5.3%. While this makes some nervous after a year of huge gains for tech, history tells us this likely means more gains are coming. There have only been 10 times ion history when the Nasdaq 100 went on a ten-day winning streak, and the average gain in the year following was 19%.
FINSUM: The point here is that even if value stocks do well—which they have been as the economic outlook has brightened—tech stocks don’t look bearish by any means.
JP Morgan put out an interesting recommendation to investors recently. They said the best place to make money in the recovery might not be in the US, but rather in international stocks. According to Gabriela Santos, global market strategist at JP Morgan Asset Management, “When you have a cyclical recovery like we expect in 2021, it’s really international’s time to shine … We think it’s really important for investors to have a balance between U.S. equity exposure and international exposure as we go into the year of the vaccine for 2021”. The key argument here is that international indexes are more dominated by cyclical stocks than tech, and those are the share poised to really gain as the vaccine plays out.
FINSUM: This is all pretty basic. International indexes have not recovered as much as US stocks, and are composed of companies that are likely to start outperforming at this stage of the recovery. Europe in particular seems to be a good bet.
New jobless data was released this morning and it took the market by surprise. Economists had been calling for new jobless claims to stay around the level of recent weeks—something around 695,00. But what happened was quite eye-opening: they came in at 853,000. The losses show that the economy is starting to feel renewed impacts of the surge in COVID cases. According to a job market expert, “Job destruction has not come to an end … We might be gaining jobs overall, but thousands of people are losing their jobs every week because demand has not returned”. Markets dipped on the release.
FINSUM: This is worrying for the economy. Hard to say if this trend will continue, but certainly not the direction markets have been predicting the economy would be heading.
US market valuations are eye-watering. By several measures the S&P 500 is as richly valued as it has ever been. With that in mind, overseas stocks, especially in Europe, appear to be a good bet. For example, while US stocks are now well ahead of their pre-COVID peaks, the Stoxx Europe 600 is still down 9.2% since its high in February. Since March, the S&P 500 has rebounded by 60% while the Stoxx Europe 600 has only seen a 40% rise.
FINSUM: So European benchmarks are more exposed to the banks and industrials, which were more hurt by COVID than US tech companies, which dominate American benchmarks. That said, now that a vaccine is in site, there is a big chance for appreciation in Europe that seems much less likely to occur in the US.